ArticleProceedings of the National Academy of Sciences of the United States of America2026
PARP7 protects the lung epithelial barrier from diverse environmental threats.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Poly-ADP-ribose polymerase (PARP) family proteins are involved in a wide range of cellular processes. Several PARPs are targeted by inhibitors as treatments for cancer based on their biochemical functions; however, the physiological functions of most PARPs and the potential adverse effects of PARP inhibition are unknown. Here, we show that PARP7 is important for lung physiology. Loss of PARP7 in mice increases susceptibility to chemically induced diffuse alveolar hemorrhaging (DAH) and pristane-induced lupus. Single-nucleus RNA-seq reveals that PARP7 is selectively expressed in alveolar type I cells and PARP7 loss increases immune cell infiltration within the lung, indicating a loss of epithelial barrier integrity. Further, PARP7 inhibition in human bronchial epithelial cells in air-liquid interface culture leads to increased barrier permeability after cigarette smoke challenge or bacterial infection. Mechanistically, we show that PARP7 target, aryl hydrocarbon receptor (AHR), mediates diverse cellular responses to cigarette smoke challenge, including loss of tight junction protein Occludin and increased expression of xenobiotic metabolizing genes and proinflammatory genes. Together, our study uncovers PARP7 as a key player in maintaining the epithelial barrier integrity within the lung, which may have important implications for pulmonary diseases and for guiding PARP7 inhibitor use in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.